Clinical trials: Malignancies Multiple
Non-Hodgkin's Lymphoma, Hodgkin Lymphoma
Safety Study of Anti-Programmed Death-Ligand 1 in Hematologic Malignancy
The purpose of this study is to determine the side effects of treatment with the monoclonal antibody anti-PD-L1 (BMS-936559) in subjects with compromised bone marrow function and the dose that should be recommended for use in…
- Conditions
- Non-Hodgkin's Lymphoma, Hodgkin Lymphoma, Multiple Myeloma, Chronic Myelogenous Leukemia
- Trial name
- NCT01452334
- Testing
- BMS-936559 (Anti PD-L1)
- Sponsor
- Bristol-Myers Squibb
Pancreatic Neoplasms
Larotaxel Compared To Continuous Administration of 5-FU in Advanced Pancreatic Cancer Patients Previously Treated With A Gemcitabine-Containing Regimen
The purpose of this study is to compare the efficacy and the safety Larotaxel administered as single agent every 3 weeks to continuous administration of 5-FU every 3 weeks, in patients with advanced pancreatic cancer (non…
- Trial name
- PAPRIKA (NCT00417209)
- Testing
- Larotaxel (XRP9881), 5-Fluorouracil, Capecitabine
- Where
- 21 sites in United States, Belgium and 19 more
- Volunteers
- 408 people
- Sponsor
- Sanofi
Relapsed or Refractory Multiple Myeloma
A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma
The purpose of this study is to evaluate the safety and tolerability of mRNA-2808 in participants with relapsed or refractory multiple myeloma (RRMM).
- Trial name
- NCT07116616
- Testing
- mRNA-2808
- Where
- 10 sites in United States
- Volunteers
- 190 people
- Sponsor
- ModernaTX, Inc.
Multiple Myeloma
A Phase 1 Study Evaluating CPI-0610 in Patients With Previously Treated Multiple Myeloma
Open-label, sequential dose escalation and expansion study of CPI-0610 in patients with previously treated multiple myeloma. CPI-0610 is a small molecule inhibitor of bromodomain and extra-terminal (BET) proteins.
- Trial name
- NCT02157636
- Testing
- CPI-0610
- Volunteers
- 30 people
- Sponsor
- Constellation Pharmaceuticals
Advanced Solid Tumor, Recurrent Endometrial Cancer
Study of ART0380 in Patients With Biologically Selected Solid Tumors
This interventional study will evaluate the efficacy and safety of ART0380 as monotherapy in patients whose tumors have a biology to predict for sensitivity to inhibition of Ataxia-Telangiectasia Mutated and Rad3-related protein…
- Conditions
- Advanced Solid Tumor, Recurrent Endometrial Cancer, Metastatic Cancer
- Trial name
- ARTIST (NCT05798611)
- Testing
- ART0380
- Where
- 15 sites in United States, France and 1 more
- Volunteers
- 36 people
- Sponsor
- Artios Pharma Ltd
Multiple Myeloma
A Study of the Combination of Belantamab Mafodotin, Bortezomib, and Dexamethasone (BVd) in Participants With Multiple Myeloma and Moderate Hepatic Impairment
The goal of the clinical trial is to collect safety data and information on how the body processes BVd in people with multiple myeloma (MM) who have moderate liver problems, compared with similar participants who have normal…
- Trial name
- NCT07609706
- Testing
- Belantamab mafodotin, Bortezomib, Dexamethasone
- Volunteers
- 20 people
- Sponsor
- GlaxoSmithKline
Seborrheic Keratosis
Study to Evaluate the Safety and Efficacy of PEP005(Ingenol Mebutate) Gel, 0.05%, in Patients With Seborrhoeic Keratosis
This study is primarily designed to investigate whether treatment, once daily for up to three consecutive days, with PEP005 (ingenol mebutate) Gel, 0.05% will be safe and tolerable in patients with Seborrhoeic Keratosis on…
- Trial name
- NCT01214564
- Testing
- PEP005 (ingenol mebutate) Gel
- Where
- 2 sites in Australia
- Volunteers
- 24 people
- Sponsor
- Peplin
Metastatic Triple-Negative Breast Carcinoma
Phase 2 Study to Evaluate PVX-410 + Pembrolizumab + Chemotherapy for Metastatic, PD-L1+ Triple-Negative Breast Cancer
Evaluating the combination of the investigational, multi-peptide cancer vaccine PVX-410 in combination with pembrolizumab and chemotherapy in treatment naive patients with metastatic, triple negative breast cancer who are PDL1…
- Trial name
- NCT04634747
- Testing
- PVX-410
- Volunteers
- 53 people
- Sponsor
- OncoPep, Inc.
Plasma EGFR Mutation-positive Lung Cancer
Efficiency of Icotinib in Plasma ctDNA EGFR Mutation-positive Patients Diagnosed With Lung Cancer
this single arm，open-label，multi-center study is aimed to evaluate the efficiency of icotinib in plasma ctDNA EGFR mutation-positive patients diagnosed with lung cancer
- Trial name
- CHALLENGE (NCT03346811)
- Testing
- Icotinib
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Betta Pharmaceuticals Co., Ltd.
Colorectal Cancer Stage II, Colorectal Cancer Stage III
A Phase II Clinical Trial Comparing the Efficacy of RO7198457 Versus Watchful Waiting in Patients With ctDNA-positive, Resected Stage II (High Risk) and Stage III Colorectal Cancer
This is a multi-site, open-label, Phase II, randomized, trial to compare the efficacy of RO7198457 versus watchful waiting in patients with circulating tumor DNA (ctDNA) positive, surgically resected Stage II/III rectal cancer…
- Trial name
- NCT04486378
- Testing
- RO7198457 intravenous (IV), Observational group (no intervention)
- Where
- 85 sites in United States, Belgium and 5 more
- Volunteers
- 327 people
- Sponsor
- BioNTech SE
Solid Tumor, Adult
A Study of ATTR-01 in Participants With Select Epithelial Solid Tumours
ATTR-01 is the experimental drug being studied in the ATTEST clinical trial. The drug is made from a common cold virus that has been changed to only infect and multiply in cancer cells.
- Trial name
- ATTEST (NCT06977737)
- Testing
- ATTR-01
- Where
- 8 sites in Spain, United Kingdom
- Volunteers
- 72 people
- Sponsor
- Accession Therapeutics Limited
Multiple Myeloma
A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment
This study is researching an experimental drug called linvoseltamab (called "study drug"). The study is focused on participants with newly diagnosed multiple myeloma (NDMM) who are eligible for high dose chemotherapy with…
- Trial name
- LINKER-MM4 (NCT05828511)
- Testing
- Linvoseltamab
- Where
- 32 sites in United States, France and 1 more
- Volunteers
- 149 people
- Sponsor
- Regeneron Pharmaceuticals
Biliary Tract Cancer
A Study of RC48-ADC in Subjects With HER2 Overexpressed Metastatic Biliary Tract Cancer
This study will evaluate the efficacy and safety of intravenous RC48-ADC in patients with locally advanced or metastatic HER2 overexpressed biliary tract cancer who have failed first-line chemotherapy.
- Trial name
- NCT04329429
- Testing
- RC48-ADC
- Where
- 16 sites in China
- Volunteers
- 57 people
- Sponsor
- RemeGen Co., Ltd.
Ovarian Neoplasms, Ovarian Epithelial Cancer
Phase II Study DCVAC/OvCa Added to First Line Carboplatin and Paclitaxel Newly Diagnosed Epithelial Ovarian Carcinoma
The purpose of this study is to determine whether DCVAC/OvCa added to chemotherapy (carboplatin plus paclitaxel as first line chemotherapy) may result in prolongation of progression free survival (PFS).
- Trial name
- NCT02107937
- Testing
- DCVAC/OvCa with Standard of Care, DCVAC/OvCa sequentially chemotherapy, Standard of Care
- Where
- 13 sites in Czechia, Poland
- Volunteers
- 136 people
- Sponsor
- SOTIO a.s.
Solid Tumors
Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies
The purpose of the Study is to select a dose and assess the safety and tolerability of INCB057643 as a monotherapy (Part 1 and Part 2) and in combination with standard-of-care (SOC) agents (Part 3 and Part 4) for subjects with…
- Trial name
- NCT02711137
- Testing
- INCB057643, Gemcitabine, Paclitaxel
- Where
- 18 sites in United States, Belgium and 1 more
- Volunteers
- 137 people
- Sponsor
- Incyte Corporation
Breast Cancer
A Study of GNC-035, a Tetra-specific Antibody, in Participants With Locally Advanced or Metastatic Breast Cancer
In this study, the safety, tolerability and preliminary effectiveness of GNC-035 in participants with locally advanced or metastatic Breast Cancer will be investigated to assess the dose-limiting toxicity (DLT), maximum tolerated…
- Trial name
- NCT05160545
- Testing
- GNC-035
- Where
- 6 sites in China
- Volunteers
- 36 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Ovarian Neoplasms
Evaluation of Multiple Protein and Molecular Biomarkers to Estimate Risk of Cancer in Gynecology Patients Presenting With a Pelvic Mass.
ANGLE has developed the Parsortix™ Cell Separation System (Parsortix), an automated system capable of harvesting rare circulating cells for analysis from a sample of peripheral blood based on cellular size and deformability.
- Trial name
- EMBER (NCT02781272)
- Testing
- Pelvic imaging, Blood draw, Imaging guided biopsy, surgical biopsy or surgical excision
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Angle plc
Multiple Myeloma, Refractory Multiple Myeloma
Real World Insights During Treatment for Relapsed/Refractory Multiple Myeloma with Isatuximab
This descriptive study aims to evaluate the experience of adults with relapsed or refractory multiple myeloma receiving standard of care isatuximab-irfc through collection of quantitative, qualitative and wearable data.
- Trial name
- NCT05053607
- Testing
- Digital Health Coaching Program, Fitbit
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- Pack Health
Solid Tumor
Safety, Pharmacokinetics and Clinical Activity of Oral Rigosertib in Solid Tumors
This is a phase 1 study in which 2 to 72 patients with advanced cancer will receive oral doses of rigosertib, a new investigational (unapproved) anti-cancer drug.
- Trial name
- NCT01168011
- Testing
- rigosertib
- Where
- United States
- Volunteers
- 68 people
- Sponsor
- Traws Pharma, Inc.
Multiple Myeloma
Phase I Dose Escalation of i.v. BI 836909 Monotherapy in Last Line Multiple Myeloma Patients
The primary objective of this trial is to determine the maximum tolerated dose (MTD) of BI 836909 administered by continuous i.v. infusion in patients with relapsed and/or refractory multiple myeloma.
- Trial name
- NCT02514239
- Testing
- BI 836909
- Where
- 5 sites in France, Germany
- Volunteers
- 43 people
- Sponsor
- Boehringer Ingelheim